BeyondSpring Inc. Cash and Cash Equivalents, Period Increase (Decrease)
BeyondSpring Inc. (BYSI) reported Cash and Cash Equivalents, Period Increase (Decrease) of -$11.02 million for the 3-month period ending 2020-03-31, per its 6-K filed 2020-06-11.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2020-06-11
- BeyondSpring Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2020-03-31 was -$11.02M.
- BeyondSpring Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2019-12-31 was $11.26M.
- BeyondSpring Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2019-09-30 was $24.00M.
- BeyondSpring Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2019-06-30 was -$1.29M, a 221.07% decline year-over-year.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2020-03-31 | -$11.02M 6-K · filed 2020-06-11 | $239.00K derived: sum of 2 quarters · filed 2020-06-11 | $24.24M derived: sum of 3 quarters · filed 2020-06-11 | $22.96M derived: sum of 4 quarters · filed 2020-06-11 |
| 2019-12-31 | $11.26M derived: 20-F 12 month − 6-K 9 month · filed 2020-04-30 | $35.26M derived: sum of 2 quarters · filed 2020-04-30 | $33.97M derived: sum of 3 quarters · filed 2020-04-30 | $32.04M 20-F · filed 2020-04-30 |
| 2019-09-30 | $24.00M derived: 6-K 9 month − 6-K 6 month · filed 2019-12-18 | $22.72M derived: sum of 2 quarters · filed 2019-12-18 | $20.79M 6-K · filed 2019-12-18 | $11.84M derived: sum of 4 quarters · filed 2020-06-11 |
| 2019-06-30 | -$1.29M derived: 6-K 6 month − 6-K 3 month · filed 2019-09-18 | -$3.21M 6-K · filed 2019-09-18 | -$12.16M derived: sum of 3 quarters · filed 2020-06-11 | -$18.74M derived: sum of 4 quarters · filed 2020-06-11 |
| 2019-03-31 | -$1.93M 6-K · filed 2020-06-11 | -$10.88M derived: sum of 2 quarters · filed 2020-06-11 | -$17.45M derived: sum of 3 quarters · filed 2020-06-11 | -$16.39M derived: sum of 4 quarters · filed 2020-06-11 |
| 2018-12-31 | -$8.95M derived: 20-F 12 month − 6-K 9 month · filed 2020-04-30 | -$15.52M derived: sum of 2 quarters · filed 2020-04-30 | -$14.46M derived: sum of 3 quarters · filed 2020-04-30 | -$23.59M 20-F · filed 2020-04-30 |
| 2018-09-30 | -$6.57M derived: 6-K 9 month − 6-K 6 month · filed 2019-12-18 | -$5.51M derived: sum of 2 quarters · filed 2019-12-18 | -$14.64M 6-K · filed 2019-12-18 | -$24.88M derived: sum of 4 quarters · filed 2020-04-30 |
| 2018-06-30 | $1.06M derived: 6-K 6 month − 6-K 3 month · filed 2019-09-18 | -$8.07M 6-K · filed 2019-09-18 | -$18.30M derived: sum of 3 quarters · filed 2020-04-30 | -$29.57M derived: sum of 4 quarters · filed 2020-04-30 |
| 2018-03-31 | -$9.13M 6-K · filed 2019-07-10 | -$19.37M derived: sum of 2 quarters · filed 2020-04-30 | -$30.63M derived: sum of 3 quarters · filed 2020-04-30 | -$36.21M derived: sum of 4 quarters · filed 2020-04-30 |
| 2017-12-31 | -$10.24M derived: 20-F 12 month − 6-K 9 month · filed 2020-04-30 | -$21.50M derived: sum of 2 quarters · filed 2020-04-30 | -$27.08M derived: sum of 3 quarters · filed 2020-04-30 | $15.79M 20-F · filed 2020-04-30 |
| 2017-09-30 | -$11.26M derived: 6-K 9 month − 6-K 6 month · filed 2017-11-09 | -$16.85M derived: sum of 2 quarters · filed 2018-10-23 | $26.03M 6-K · filed 2017-11-09 | $20.39M derived: sum of 4 quarters · filed 2019-04-30 |
| 2017-06-30 | -$5.58M derived: 6-K 6 month − 6-K 3 month · filed 2018-10-23 | $37.29M 6-K · filed 2018-10-23 | $31.65M derived: sum of 3 quarters · filed 2019-04-30 | $43.35M derived: sum of 4 quarters · filed 2019-04-30 |
| 2017-03-31 | $42.88M 6-K · filed 2018-06-21 | $37.23M derived: sum of 2 quarters · filed 2019-04-30 | $48.93M derived: sum of 3 quarters · filed 2019-04-30 | $45.77M derived: sum of 4 quarters · filed 2019-04-30 |
| 2016-12-31 | -$5.64M derived: 20-F 12 month − 6-K 9 month · filed 2019-04-30 | $6.05M derived: sum of 2 quarters · filed 2019-04-30 | $2.89M derived: sum of 3 quarters · filed 2019-04-30 | $866.00K 20-F · filed 2019-04-30 |
| 2016-09-30 | $11.70M derived: 6-K 9 month − 6-K 6 month · filed 2017-11-09 | $8.53M derived: sum of 2 quarters · filed 2017-11-09 | $6.51M 6-K · filed 2017-11-09 | |
| 2016-06-30 | -$3.16M derived: 6-K 6 month − 6-K 3 month · filed 2017-08-21 | -$5.19M 6-K · filed 2017-08-21 | ||
| 2016-03-31 | -$2.03M 6-K · filed 2017-05-22 | |||
| 2015-12-31 | $10.43M 20-F · filed 2018-04-03 | |||
| 2014-12-31 | $384.00K 20-F · filed 2017-04-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |